News
Press Releases
2015/02/06
WuXiPRA Appoints Two Key Executives
SHANGHAI, February 6, 2015 /PRNewswire/ -- WuXiPRA, a leading clinical services company with operations in the greater China region, today announced appointments of two key executives. Liedong Xu was named Executive Vice President and Chief Operations Officer. He brings 22 years of experience in the pharmaceutical and medical device industries, including roles of increasing responsibility at MSD Allergan, Abbott Santen, and Merck Serono. Jason Wu was appointed Executive Vice President and Chief Medical Officer of WuXiPRA. His 20 years of experience in clinical practice, clinical research, and product development include management positions at Graceway, Auxillium, Sanofi, and Pfizer
Read more2015/01/30
WuXi PharmaTech's Small-Molecule Manufacturing Subsidiary STA Wins CMO Leadership Award
SHANGHAI, January 30, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announced today that SynTheAll Pharmaceutical Co., Ltd. (STA), WuXi's small-molecule manufacturing subsidiary, has won a 2015 CMO Leadership Award, which is presented by Life Science Leader magazine based on research conducted by Nice Insight. STA has won in the perception category of Reliability in the company category of Big Pharma. The award is based on the survey responses of more than 2,300 pharmaceutical and biopharmaceutical professionals. WuXi and STA also received a CMO Leadership Award for Quality in 2012.
Read more2015/01/09
WuXi PharmaTech Provides Update of 2014 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has updated its 2014 financial guidance.
Read more2015/01/05
WuXi Launches Mobile App to Enable Chemistry-on-the-Go
SHANGHAI, January 5, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced the launch of WuXi V-Lab, the first mobile app available to the global research community in need of small-molecule compound synthesis. WuXi V-Lab allows customers to request organic compound synthesis through a mobile device with ease, speed, and flexibility. The application provides online functions for inquiry, quotation, order confirmation, project tracking, delivery confirmation, and payment. WuXi V-Lab can be downloaded to an Apple or Android mobile device at: http://www.wuxiapptec.com/WXVLab
Read more